News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now

Press Release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now

News

Scribe Inks CRISPR Gene-Editing Deal with Prevail

May 19, 2023

Bloomberg

Read Now

Press Release

Scribe Inks CRISPR Gene-Editing Deal with Prevail

May 19, 2023

Bloomberg

Read Now

News

Scribe signs another big pharma deal

May 19, 2023

Evaluate

Read Now

Press Release

Scribe signs another big pharma deal

May 19, 2023

Evaluate

Read Now

News

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

May 17, 2023

BioSpace

Read Now

Press Release

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

May 17, 2023

BioSpace

Read Now

News

Scribe and Prevail partner for CRISPR-based genetic medicines

May 17, 2023

Pharmaceutical Technology

Read Now

Press Release

Scribe and Prevail partner for CRISPR-based genetic medicines

May 17, 2023

Pharmaceutical Technology

Read Now

News

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

May 17, 2023

Labiotech

Read Now

Press Release

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

May 17, 2023

Labiotech

Read Now

News

Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics

October 6, 2023

San Francisco Business Times

Read Now

News

This Scientist Is Building Custom Gene-Editing Tools

July 25, 2023

Forbes

Read Now

News

Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners

July 20, 2023

Wall Street Journal

Read Now

News

Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease

July 18, 2023

BioWorld

Read Now

News

Sanofi expands collaboration with Scribe on CRISPR genome editing

July 18, 2023

Seeking Alpha

Read Now

News

East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease

July 18, 2023

San Francisco Business Times

Read Now

Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now

Press release

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now

Press release

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Read Now

Press release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now

Press release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Read Now

Publications

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publications

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publications

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publications

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publications

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publications

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publications

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now